Hospitalization-related bone loss and the protective effect of risedronate

Robert P. Heaney, David J. Valent, Ian P. Barton

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Intercurrent illness and episodes of hospitalization and surgery are common in an aging population, who, at the same time, are experiencing age-related bone loss. The objective was to test the hypotheses (1) that intercurrent illness severe enough to require hospitalization produces clinically important bone loss, and (2) that antiresorptive therapy will reduce that loss. The study was a retrospective analysis of bone mineral density (BMD) change at hip and spine in subjects of the risedronate postmenopausal osteoporosis phase III trials experiencing serious adverse events (SAEs). Subjects were 243 hospitalized for non-skin cancers, pneumonia, myocardial infarction, cerebrovascular accident, gallbladder disease, and pancreatitis, on whom BMD data were available both before and after the SAE; and 286 non-hospitalized control subjects matched to those with SAEs by age, height, weight, prevalent fracture, and visit interval. In hospitalized, placebo-treated participants, the annualized percent change in BMD (mean ± SEM) across the period of hospitalization was -0.65 ± 0.39 at lumbar spine, -1.13 ± 0.55 at femoral neck, and -2.66 ± 0.58 at femoral trochanter; the corresponding values for the non-hospitalized, placebo controls were +0.46 ± 0.28, -0.77 ± 0.34, and -0.67 ± 0.34. These values were more negative at all three sites for the hospitalized subjects, and significantly so at lumbar spine and femoral trochanter (P = 0.019 and 0.002, respectively). By contrast, in the risedronate-treated participants, all sites exhibited bone gain and there was no significant difference between hospitalized and non-hospitalized participants. Intercurrent illness resulting in hospitalization produced a rapid bone loss across the period of illness comparable in magnitude to documented age-related loss. Risedronate in a dose of 5 mg/ day effectively abolished this loss.

Original languageEnglish
Pages (from-to)212-216
Number of pages5
JournalOsteoporosis International
Volume17
Issue number2
DOIs
StatePublished - Feb 2006

Fingerprint

Hospitalization
Bone Density
Bone and Bones
Spine
Thigh
Femur
Placebos
Gallbladder Diseases
Postmenopausal Osteoporosis
Femur Neck
Pancreatitis
Osteoporosis
Hip
Pneumonia
Stroke
Myocardial Infarction
Weights and Measures
Risedronate Sodium
Population
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Hospitalization-related bone loss and the protective effect of risedronate. / Heaney, Robert P.; Valent, David J.; Barton, Ian P.

In: Osteoporosis International, Vol. 17, No. 2, 02.2006, p. 212-216.

Research output: Contribution to journalArticle

Heaney, Robert P. ; Valent, David J. ; Barton, Ian P. / Hospitalization-related bone loss and the protective effect of risedronate. In: Osteoporosis International. 2006 ; Vol. 17, No. 2. pp. 212-216.
@article{27450901adab4614bb163d368f35ad55,
title = "Hospitalization-related bone loss and the protective effect of risedronate",
abstract = "Intercurrent illness and episodes of hospitalization and surgery are common in an aging population, who, at the same time, are experiencing age-related bone loss. The objective was to test the hypotheses (1) that intercurrent illness severe enough to require hospitalization produces clinically important bone loss, and (2) that antiresorptive therapy will reduce that loss. The study was a retrospective analysis of bone mineral density (BMD) change at hip and spine in subjects of the risedronate postmenopausal osteoporosis phase III trials experiencing serious adverse events (SAEs). Subjects were 243 hospitalized for non-skin cancers, pneumonia, myocardial infarction, cerebrovascular accident, gallbladder disease, and pancreatitis, on whom BMD data were available both before and after the SAE; and 286 non-hospitalized control subjects matched to those with SAEs by age, height, weight, prevalent fracture, and visit interval. In hospitalized, placebo-treated participants, the annualized percent change in BMD (mean ± SEM) across the period of hospitalization was -0.65 ± 0.39 at lumbar spine, -1.13 ± 0.55 at femoral neck, and -2.66 ± 0.58 at femoral trochanter; the corresponding values for the non-hospitalized, placebo controls were +0.46 ± 0.28, -0.77 ± 0.34, and -0.67 ± 0.34. These values were more negative at all three sites for the hospitalized subjects, and significantly so at lumbar spine and femoral trochanter (P = 0.019 and 0.002, respectively). By contrast, in the risedronate-treated participants, all sites exhibited bone gain and there was no significant difference between hospitalized and non-hospitalized participants. Intercurrent illness resulting in hospitalization produced a rapid bone loss across the period of illness comparable in magnitude to documented age-related loss. Risedronate in a dose of 5 mg/ day effectively abolished this loss.",
author = "Heaney, {Robert P.} and Valent, {David J.} and Barton, {Ian P.}",
year = "2006",
month = "2",
doi = "10.1007/s00198-005-1975-4",
language = "English",
volume = "17",
pages = "212--216",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "2",

}

TY - JOUR

T1 - Hospitalization-related bone loss and the protective effect of risedronate

AU - Heaney, Robert P.

AU - Valent, David J.

AU - Barton, Ian P.

PY - 2006/2

Y1 - 2006/2

N2 - Intercurrent illness and episodes of hospitalization and surgery are common in an aging population, who, at the same time, are experiencing age-related bone loss. The objective was to test the hypotheses (1) that intercurrent illness severe enough to require hospitalization produces clinically important bone loss, and (2) that antiresorptive therapy will reduce that loss. The study was a retrospective analysis of bone mineral density (BMD) change at hip and spine in subjects of the risedronate postmenopausal osteoporosis phase III trials experiencing serious adverse events (SAEs). Subjects were 243 hospitalized for non-skin cancers, pneumonia, myocardial infarction, cerebrovascular accident, gallbladder disease, and pancreatitis, on whom BMD data were available both before and after the SAE; and 286 non-hospitalized control subjects matched to those with SAEs by age, height, weight, prevalent fracture, and visit interval. In hospitalized, placebo-treated participants, the annualized percent change in BMD (mean ± SEM) across the period of hospitalization was -0.65 ± 0.39 at lumbar spine, -1.13 ± 0.55 at femoral neck, and -2.66 ± 0.58 at femoral trochanter; the corresponding values for the non-hospitalized, placebo controls were +0.46 ± 0.28, -0.77 ± 0.34, and -0.67 ± 0.34. These values were more negative at all three sites for the hospitalized subjects, and significantly so at lumbar spine and femoral trochanter (P = 0.019 and 0.002, respectively). By contrast, in the risedronate-treated participants, all sites exhibited bone gain and there was no significant difference between hospitalized and non-hospitalized participants. Intercurrent illness resulting in hospitalization produced a rapid bone loss across the period of illness comparable in magnitude to documented age-related loss. Risedronate in a dose of 5 mg/ day effectively abolished this loss.

AB - Intercurrent illness and episodes of hospitalization and surgery are common in an aging population, who, at the same time, are experiencing age-related bone loss. The objective was to test the hypotheses (1) that intercurrent illness severe enough to require hospitalization produces clinically important bone loss, and (2) that antiresorptive therapy will reduce that loss. The study was a retrospective analysis of bone mineral density (BMD) change at hip and spine in subjects of the risedronate postmenopausal osteoporosis phase III trials experiencing serious adverse events (SAEs). Subjects were 243 hospitalized for non-skin cancers, pneumonia, myocardial infarction, cerebrovascular accident, gallbladder disease, and pancreatitis, on whom BMD data were available both before and after the SAE; and 286 non-hospitalized control subjects matched to those with SAEs by age, height, weight, prevalent fracture, and visit interval. In hospitalized, placebo-treated participants, the annualized percent change in BMD (mean ± SEM) across the period of hospitalization was -0.65 ± 0.39 at lumbar spine, -1.13 ± 0.55 at femoral neck, and -2.66 ± 0.58 at femoral trochanter; the corresponding values for the non-hospitalized, placebo controls were +0.46 ± 0.28, -0.77 ± 0.34, and -0.67 ± 0.34. These values were more negative at all three sites for the hospitalized subjects, and significantly so at lumbar spine and femoral trochanter (P = 0.019 and 0.002, respectively). By contrast, in the risedronate-treated participants, all sites exhibited bone gain and there was no significant difference between hospitalized and non-hospitalized participants. Intercurrent illness resulting in hospitalization produced a rapid bone loss across the period of illness comparable in magnitude to documented age-related loss. Risedronate in a dose of 5 mg/ day effectively abolished this loss.

UR - http://www.scopus.com/inward/record.url?scp=30144438104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30144438104&partnerID=8YFLogxK

U2 - 10.1007/s00198-005-1975-4

DO - 10.1007/s00198-005-1975-4

M3 - Article

VL - 17

SP - 212

EP - 216

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 2

ER -